Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1997 3
1998 1
1999 1
2000 3
2001 1
2002 2
2003 1
2004 2
2005 2
2006 2
2007 1
2008 4
2009 6
2010 4
2011 2
2012 2
2013 4
2014 2
2016 2
2017 4
2018 3
2019 5
2020 4
2021 6
2022 9
2023 3
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. Fossati N, et al. Among authors: matveev vb. Eur Urol. 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003. Epub 2017 Jan 24. Eur Urol. 2017. PMID: 28126351 Free article.
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. McDermott DF, et al. Among authors: matveev vb. J Clin Oncol. 2021 Mar 20;39(9):1029-1039. doi: 10.1200/JCO.20.02365. Epub 2021 Feb 2. J Clin Oncol. 2021. PMID: 33529058 Free PMC article. Clinical Trial.
[Paratesticular rhabdomyosarcoma].
Mamveev BP, Gurariĭ LL, Volkova MI, Matveev VB, Khalaf'ian EA. Mamveev BP, et al. Among authors: matveev vb. Urologiia. 2003 Mar-Apr;(2):18-21. Urologiia. 2003. PMID: 12811918 Russian.
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS, Attard G, Åström L, Matveev VB, Bracarda S, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Boysen G, Gourgioti G, Martins K, Chowdhury S. Merseburger AS, et al. Among authors: matveev vb. Lancet Oncol. 2022 Nov;23(11):1398-1408. doi: 10.1016/S1470-2045(22)00560-5. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265504 Clinical Trial.
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.
Ruiz-Vico M, Wetterskog D, Orlando F, Thakali S, Wingate A, Jayaram A, Cremaschi P, Vainauskas O, Brighi N, Castellano-Gauna D, Åström L, Matveev VB, Bracarda S, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Gupta S, Wenstrup R, Boysen G, Martins K, Iwata K, Chowdhury S, Gourgioti G, Serikoff A, Gonzalez-Billalabeitia E, Merseburger AS, Demichelis F, Attard G. Ruiz-Vico M, et al. Among authors: matveev vb. Eur Urol Oncol. 2025 Feb;8(1):135-144. doi: 10.1016/j.euo.2024.08.006. Epub 2024 Sep 11. Eur Urol Oncol. 2025. PMID: 39261236 Free article. Clinical Trial.
DKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells.
Bley IA, Zwick A, Hans MC, Thieser K, Wagner V, Ludwig N, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Naumann CM, Kalthoff H, Junker K, Smola S, Lohse S. Bley IA, et al. Among authors: matveev vb. Transl Oncol. 2022 Jan;15(1):101267. doi: 10.1016/j.tranon.2021.101267. Epub 2021 Nov 10. Transl Oncol. 2022. PMID: 34773828 Free PMC article. Review.
[EAU guidelines on prostate cancer].
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F; European Association of Urology. Heidenreich A, et al. Among authors: matveev vb. Actas Urol Esp. 2009 Feb;33(2):113-26. doi: 10.1016/s0210-4806(09)74110-5. Actas Urol Esp. 2009. PMID: 19418833 Spanish.
The impact of the tumor microenvironment on the survival of penile cancer patients.
Lohse S, Mink JN, Eckhart L, Hans MC, Jusufi L, Zwick A, Mohr T, Bley IA, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Lenhof HP, Naumann CM, Kalthoff H, Junker K. Lohse S, et al. Among authors: matveev vb. Sci Rep. 2024 Sep 27;14(1):22050. doi: 10.1038/s41598-024-70855-z. Sci Rep. 2024. PMID: 39333233 Free PMC article.
EAU guidelines on prostate cancer.
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F; European Association of Urology. Heidenreich A, et al. Among authors: matveev vb. Eur Urol. 2008 Jan;53(1):68-80. doi: 10.1016/j.eururo.2007.09.002. Epub 2007 Sep 19. Eur Urol. 2008. PMID: 17920184
78 results